WIN 2017 Symposium will be held in Paris, France from June 26-27, 2017.
Posted: Thursday, February 09, 2017
VILLEJUIF, France--(BUSINESS WIRE)--WIN 2017 Symposium will be held in Paris, France from June 26-27, 2017. The CME accredited WIN2017 is an exceptional scientific event dedicated to “Expediting Global Innovation in Precision Cancer Medicine’’ addressed to all cancer care professionals.
“The 2016 WIN symposium brought together some of most distinguished lecturers from around the world covering a broad array of topics that are likely to have a direct impact on the treatment of most of our patients with cancer.” said Bruce E. Johnson, President of ASCO® 2017-2018, who delivered a keynote lecture in the last edition. ASCO® has endorsed the WIN Symposium for the past eight consecutive years.
John Mendelsohn, Chair of WIN Consortium and Past President of The University of Texas MD Anderson Cancer Center will present in his Welcome Address an overview of WIN disruptive programs aiming to significantly improve lung cancer patients’ outcomes.
José Baselga, Memorial Sloan Kettering Cancer Center will discuss in Keynote Opening Lecture “Genomic-driven Clinical Studies in Breast Cancer”.
The Closing Keynote lecture and remarks will be presented by Leroy Hood from Institute for Systems Biology.
The scientific program brings together the greatest academic and industry experts and will develop the following themes:
Innovation in clinical trial design – Razelle Kurzrock (UCSD), Laura Esserman (UCSF), Donald A. Berry and J Jack Lee (UT-MD Anderson)
New avenues for target discovery - Geneviève Almouzni (Institut Curie) and Giorgio Massimini (Merck Serono)
Immunological approach to personalized medicine – Antoni Ribas (UCLA), Guido Kroemer (Gustave Roussy), Hans-Georg Rammensee (University of Tübingen) and Steven Anderson (Covance)
Next great steps in cancer therapy – Olli Kallioniemi (Karolinska Institutet & FIMM), Henry Rodriguez (NCI) and Peter Lichter (DFKZ)
Predict: what and how? – Martine J. Piccart-Gebhart (Jules Bordet), Jean-François Martini (Pfizer), Maureen Sullivan (Blue Cross Blue Shield), Caroline Robert (Gustave Roussy)
Using new knowledge in clinical trials – René Bernards (NKI), Daniel F. Hayes (University of Michigan, President of ASCO® 2016-2017), Reinhardt Büttner (University Hospital of Cologne), Stefan Pfister (DKFZ) and Robert G. Bristow (Princess Margaret)
There will be open discussion with audience participation on each of these topics. In addition, three forums with open discussion for all attendees will debate on how to deliver better treatments to patients and improving their outcomes and these will be published in a synopsis of the symposium.
Trends of clinical trial design, moderated by Razelle Kurzrock (UCSD) and Brian Leyland-Jones (AVERA)
Place of immunotherapy approaches in precision cancer care, moderated by Antoni Ribas (UCLA) and Jean-Yves Blay (Centre Léon Bérard)
Challenges of real world implementation of precision medicine and implications for other diseases, moderated by Lisa Hutchinson (Nature Publishing Group) and Thomas Tursz (Fondation ARC) with the exceptional participation of Otmar D. Wiestler (Helmholtz Association) and Richard L. Schilsky (ASCO®)
The authors of the two best posters will be awarded with a prize of 750 euros and invited to an oral presentation at the Symposium.
The Symposium exhibition area is open to all industry to showcase and share their latest research and interact with attendees. The WIN symposium provides excellent networking opportunities between all professionals in cancer care.
For more information, take a look at www.winsymposium.org
For sponsoring opportunities contact: email@example.com
About WIN: WIN Consortium is a non-profit organization based in Paris, France. We are a worldwide network assembling cancer stakeholders from four continents to develop cutting edge concepts and clinical trials that improve survival for cancer patients. WIN members include 28 outstanding cancer centers plus 9 additional leading pharmaceutical, technology companies and patient advocacy organizations representing stakeholders in precision cancer medicine, www.winconsortium.org
ASCO® and American Society of Clinical Oncology® are registered trademarks of the American Society of Clinical Oncology, Inc. Used with permission. This is not an ASCO® sponsored event.
Vladimir Lazar, Telephone: 00 33 66 109 15 22
Chief Scientific and Operating Officer
Diversity of Stakeholders - WIN Members
Studies with a global population
Sharing information to promote use of personalized, targeted cancer therapy: WIN Symposia
WIN was created to accelerate the pace and reduce the cost of translating novel cancer treatments to the bedside by developing and applying, through worldwide clinical trials and research projects, the most promising advances in genomic-based cancer research. WIN aims to initiate research projects each year in a global consortium guided by an independent scientific advisory board.
WIN now includes 43 institutional members. These stakeholders have come together from all parts of the world to address the challenge of increasing the efficacy of cancer diagnostics and therapeutics by understanding the genetics and biology of each individual’s tumor and accounting for genetic differences across diverse populations—from North and South America, Europe, Asia, and the Middle East.
Our goal is to significantly improve outcomes for patients around the globe. We aim to increase the number of patients worldwide that have access to innovative, global clinical trials in the area of genomic-based cancer therapeutics. Global diversity and inclusion of all stakeholders is WIN’s most important and differentiating asset.
Our members include leading academic, pharmaceutical, life science, not-for-profit, health IT, and healthpayer organizations.
WIN's first trial, WINTHER, is currently being carried out through a collaboration between six academic centers in five countries, with key support from Europe (EUFP7), Fondation ARC, Pfizer and other pharma companies.